UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 290

Sortiert nach

CD33 Splicing Polymorphism Determines Gemtuzumab Ozogamicin Response in De Novo Acute Myeloid Leukemia: Report From Randomized Phase III Children's Oncology Group Trial AAML0531

Journal of clinical oncology, 2017-08, Vol.35 (23), p.2674-2682

2017

Volltextzugriff (PDF)

Gemtuzumab Ozogamicin Reduces Relapse Risk in FLT3/ITD Acute Myeloid Leukemia: A Report from the Children's Oncology Group

Clinical cancer research, 2016-04, Vol.22 (8), p.1951-1957

2016

Volltextzugriff (PDF)

Measuring response to therapy in AML: Difference from normal flow cytometry vs RQ-PCR

Methods in cell biology, 2024, Vol.186, p.233-247

2024

Volltextzugriff (PDF)

Sorafenib in Combination With Standard Chemotherapy for Children With High Allelic Ratio FLT3 /ITD+ Acute Myeloid Leukemia: A Report From the Children's Oncology Group Protocol AAML1031

Journal of clinical oncology, 2022-06, Vol.40 (18), p.2023-2035

2022

Volltextzugriff (PDF)

Bortezomib with standard chemotherapy for children with acute myeloid leukemia does not improve treatment outcomes: a report from the Children's Oncology Group

Haematologica (Roma), 2020-07, Vol.105 (7), p.1879

2020

Volltextzugriff (PDF)

CEBPA-bZip mutations are associated with favorable prognosis in de novo AML: a report from the Children's Oncology Group

Blood, 2021-09, Vol.138 (13), p.1137-1147

2021

Volltextzugriff (PDF)

Residual disease detected by multidimensional flow cytometry signifies high relapse risk in patients with de novo acute myeloid leukemia: a report from Children's Oncology Group

Blood, 2012-08, Vol.120 (8), p.1581-1588

2012

Volltextzugriff (PDF)

NUP98/NSD1 and FLT3/ITD coexpression is more prevalent in younger AML patients and leads to induction failure: a COG and SWOG report

Blood, 2014-10, Vol.124 (15), p.2400-2407

2014

Volltextzugriff (PDF)

Comprehensive Transcriptome Profiling of Cryptic CBFA2T3-GLIS2 Fusion-Positive AML Defines Novel Therapeutic Options: A COG and TARGET Pediatric AML Study

Clinical cancer research, 2020-02, Vol.26 (3), p.726-737

2020

Volltextzugriff (PDF)

CBFA2T3-GLIS2 model of pediatric acute megakaryoblastic leukemia identifies FOLR1 as a CAR T cell target

The Journal of clinical investigation, 2022-11, Vol.132 (22), p.1-17

2022

Volltextzugriff (PDF)

CD123 Expression Is Associated With High-Risk Disease Characteristics in Childhood Acute Myeloid Leukemia: A Report From the Children's Oncology Group

Journal of clinical oncology, 2022-01, Vol.40 (3), p.252-261

2022

Volltextzugriff (PDF)

Functional Properties of KIT Mutations Are Associated with Differential Clinical Outcomes and Response to Targeted Therapeutics in CBF Acute Myeloid Leukemia

Clinical cancer research, 2019-08, Vol.25 (16), p.5038-5048

2019

Volltextzugriff (PDF)

Therapeutic Targeting of Mesothelin with Chimeric Antigen Receptor T Cells in Acute Myeloid Leukemia

Clinical cancer research, 2021-10, Vol.27 (20), p.5718-5730

2021

Volltextzugriff (PDF)

A longitudinal single-cell atlas of treatment response in pediatric AML

Cancer cell, 2023-12, Vol.41 (12), p.2117-2135.e12

2023

Volltextzugriff (PDF)

Evidence for BCR/ABL1‐positive T‐cell acute lymphoblastic leukemia arising in an early lymphoid progenitor cell

Pediatric blood & cancer, 2019-09, Vol.66 (9), p.e27829-n/a

2019

Volltextzugriff (PDF)

CCGG deletion (rs201074739) in CD33 results in premature termination codon and complete loss of CD33 expression: another key variant with potential impact on response to CD33-directed agents

Leukemia & lymphoma, 2019-07, Vol.60 (9), p.2287-2290

2019

Volltextzugriff (PDF)

A B-cell developmental gene regulatory network is activated in infant AML

PloS one, 2021-11, Vol.16 (11), p.e0259197-e0259197

2021

Volltextzugriff (PDF)

Residual disease in AML, a target that can move in more than one direction

Cytometry. Part B, Clinical cytometry, 2014-01, Vol.86 (1), p.15-17

Loken, Michael R.

2014

Volltextzugriff (PDF)

Phenotype in combination with genotype improves outcome prediction in acute myeloid leukemia: a report from Children's Oncology Group protocol AAML0531

Haematologica (Roma), 2017-12, Vol.102 (12), p.2058

2017

Volltextzugriff (PDF)

CD33 splicing SNP regulates expression levels of CD33 in normal regenerating monocytes in AML patients

Leukemia & lymphoma, 2018-09, Vol.59 (9), p.2250-2253

2018

Volltextzugriff (PDF)

Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33‐positive acute myeloid leukemia in first recurrence

Cancer, 2005-10, Vol.104 (7), p.1442-1452

2005

Volltextzugriff (PDF)

Definitions and standards in the diagnosis and treatment of the myelodysplastic syndromes: Consensus statements and report from a working conference

Leukemia research, 2007-06, Vol.31 (6), p.727-736

2007

Volltextzugriff (PDF)

The impact of Down syndrome‐specific non‐malignant hematopoietic regeneration in the bone marrow on the detection of leukemic measurable residual disease

Cytometry. Part B, Clinical cytometry, 2023-07, Vol.104 (4), p.311-318

2023

Volltextzugriff (PDF)

Multiparameter flow cytometry in the evaluation of myelodysplasia: Analytical issues: Recommendations from the European LeukemiaNet/International Myelodysplastic Syndrome Flow Cytometry Working Group

Cytometry. Part B, Clinical cytometry, 2023-01, Vol.104 (1), p.27-50

2023

Volltextzugriff (PDF)

1 – 25 von 290

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(246)
Mit Volltextzugriff
(269)

Publikationsform

1 weiteren anzeigen...

Weniger anzeigen...

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

CD33 Splicing Polymorphism Determines Gemtuzumab Ozogamicin Response in De Novo Acute Myeloid Leukemia: Report From Randomized Phase III Children's Oncology Group Trial AAML0531

Gemtuzumab Ozogamicin Reduces Relapse Risk in FLT3/ITD Acute Myeloid Leukemia: A Report from the Children's Oncology Group

Measuring response to therapy in AML: Difference from normal flow cytometry vs RQ-PCR

Sorafenib in Combination With Standard Chemotherapy for Children With High Allelic Ratio FLT3 /ITD+ Acute Myeloid Leukemia: A Report From the Children's Oncology Group Protocol AAML1031

Bortezomib with standard chemotherapy for children with acute myeloid leukemia does not improve treatment outcomes: a report from the Children's Oncology Group

CEBPA-bZip mutations are associated with favorable prognosis in de novo AML: a report from the Children's Oncology Group

Residual disease detected by multidimensional flow cytometry signifies high relapse risk in patients with de novo acute myeloid leukemia: a report from Children's Oncology Group

NUP98/NSD1 and FLT3/ITD coexpression is more prevalent in younger AML patients and leads to induction failure: a COG and SWOG report

Comprehensive Transcriptome Profiling of Cryptic CBFA2T3-GLIS2 Fusion-Positive AML Defines Novel Therapeutic Options: A COG and TARGET Pediatric AML Study

CBFA2T3-GLIS2 model of pediatric acute megakaryoblastic leukemia identifies FOLR1 as a CAR T cell target

CD123 Expression Is Associated With High-Risk Disease Characteristics in Childhood Acute Myeloid Leukemia: A Report From the Children's Oncology Group

Functional Properties of KIT Mutations Are Associated with Differential Clinical Outcomes and Response to Targeted Therapeutics in CBF Acute Myeloid Leukemia

Proposed minimal diagnostic criteria for myelodysplastic syndromes (MDS) and potential pre-MDS conditions

Therapeutic Targeting of Mesothelin with Chimeric Antigen Receptor T Cells in Acute Myeloid Leukemia

A longitudinal single-cell atlas of treatment response in pediatric AML

Evidence for BCR/ABL1‐positive T‐cell acute lymphoblastic leukemia arising in an early lymphoid progenitor cell

CCGG deletion (rs201074739) in CD33 results in premature termination codon and complete loss of CD33 expression: another key variant with potential impact on response to CD33-directed agents

A B-cell developmental gene regulatory network is activated in infant AML

Residual disease in AML, a target that can move in more than one direction

Phenotype in combination with genotype improves outcome prediction in acute myeloid leukemia: a report from Children's Oncology Group protocol AAML0531

CD33 splicing SNP regulates expression levels of CD33 in normal regenerating monocytes in AML patients

Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33‐positive acute myeloid leukemia in first recurrence

Definitions and standards in the diagnosis and treatment of the myelodysplastic syndromes: Consensus statements and report from a working conference

The impact of Down syndrome‐specific non‐malignant hematopoietic regeneration in the bone marrow on the detection of leukemic measurable residual disease

Multiparameter flow cytometry in the evaluation of myelodysplasia: Analytical issues: Recommendations from the European LeukemiaNet/International Myelodysplastic Syndrome Flow Cytometry Working Group

Suchergebnisse filtern